A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma

Prior treatment

• Subjects who received a live vaccine within 4 weeks prior to the first dose or are scheduled to receive a live vaccine during the study treatment period and within 4 weeks after the last dose.

Other illness

• Participants with mental illness (impairing understanding or ability to give informed consent),history of Drug abuse, alcoholism or drug addiction.
• participant had a history of severe cardiovascular and cerebrovascular disorder.
• patients with active,Or patients who have had and may recur autoimmune diseases.
• patients with active hepatitis B or active hepatitis C.
• History of immunodeficiency including HIV antibody test positive.
• The investigator believes that the subject has other conditions that may affect compliance or are not suitable for participating in this study.

Other

• Participants with clinically uncontrollable pleural effusion, pericardial effusion, ascites, and those requiring repeated drainage or medical intervention.
• Women during pregnancy or lactation.

• Agree to follow the trial treatment regimen, visit schedule, laboratory test, and other requirements of the protocol, and voluntarily enroll in the study and sign the written informed consent.
• Age 18-75 years (inclusive of boundaries) at the time of signing informed consent form.
• The Eastern Cooperative Oncology Group's physical status scoring standard (ECOG) is 0\~1.
• The expected survival time is at least 12 weeks.
• According to the evaluation of RECIST 1.1 （Response Evaluation Criteria in Solid Tumours），the Participants enrolled have at least one measurable lesion.
• There is adequate organ and bone marrow function,Conforms to laboratory test results.
• Male of childbearing potential and Females of childbearing age are willing to take highly effective contraceptive measures From the signing of the informed consent form to within 6 months after the last administration of the trial drug.